Co-Authors
This is a "connection" page, showing publications co-authored by Carlo Perno and Massimo Puoti.
Connection Strength
1.560
-
SARS-CoV-2 RNA in plasma samples of COVID-19 affected individuals: a cross-sectional proof-of-concept study. BMC Infect Dis. 2021 Feb 17; 21(1):184.
Score: 0.232
-
Mild Course of SARS-CoV-2 Infection in a Liver Transplant Recipient Undergoing Plasma Exchange and Defibrotide for Acute Graft Rejection. Transplantation. 2021 02 01; 105(2):e22-e24.
Score: 0.232
-
Effectiveness of infection-containment measures on SARS-CoV-2 seroprevalence and circulation from May to July 2020, in Milan, Italy. PLoS One. 2020; 15(11):e0242765.
Score: 0.229
-
Detection and quantification of SARS-CoV-2 by droplet digital PCR in real-time PCR negative nasopharyngeal swabs from suspected COVID-19 patients. PLoS One. 2020; 15(9):e0236311.
Score: 0.225
-
Persistent positivity and fluctuations of SARS-CoV-2 RNA in clinically-recovered COVID-19 patients. J Infect. 2020 Sep; 81(3):e90-e92.
Score: 0.222
-
Nasopharyngeal SARS-CoV-2 Load at Hospital Admission as a Predictor of Mortality. Clin Infect Dis. 2021 05 18; 72(10):1868-1869.
Score: 0.059
-
Frontline Screening for SARS-CoV-2 Infection at Emergency Department Admission by Third Generation Rapid Antigen Test: Can We Spare RT-qPCR? Viruses. 2021 05 01; 13(5).
Score: 0.059
-
Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy. Nat Commun. 2021 01 19; 12(1):434.
Score: 0.058
-
Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis. J Infect. 2020 10; 81(4):e11-e17.
Score: 0.056
-
Real life experiences in HCV management in 2018. Expert Rev Anti Infect Ther. 2019 02; 17(2):117-128.
Score: 0.050
-
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. Sci Rep. 2018 06 12; 8(1):8988.
Score: 0.048
-
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens. PLoS One. 2017; 12(5):e0177352.
Score: 0.045
-
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. Lancet Gastroenterol Hepatol. 2017 06; 2(6):427-434.
Score: 0.044